Company News

Company News

English

Polaris Group Announces Positive Top-Line Results from Phase 2/3 ATOMIC study in Patients with Malignant Pleural Mesothelioma to Assess ADI-PEG 20 with Pemetrexed and Cisplatin

TAIPEI, Taiwan and SAN DIEGO, Calif., September 21, 2022 — Polaris Group (TWSE: 6550), a multinational biopharmaceutical company focused on research and development of novel biological drugs for cancer and other metabolic diseases, today announced top-line efficacy and safety data from the Phase 2/3 ATOMIC Study, a global, multi-center, randomized, double-blind, placebo-controlled trial of ADI-PEG 20 in combination with Pemetrexed and Cisplatin in patients with unresectable Malignant Pleural Mesothelioma (MPM) with biphasic or sarcomatoid histology.

Read More
English

Polaris Group Announces its listing on the Taiwan Stock Exchange on June 6, 2022

TAIPEI, Taiwan and SAN DIEGO, Calif., June 6, 2022 – Polaris Group (“Polaris”) (TWSE: 6550), a multinational biopharmaceutical company focused on research and development of novel biological drugs for cancer and other metabolic diseases

Read More
English

Polris Group received approval from the Listing Review Committee of Taiwan Stock Exchange for Primary Listing

The Taiwan Stock Exchange Corporation held its 755th Listing Review Committee meeting on March 4, 2022 and approved the application of Polaris Group for primary …

Read More
English

Polaris Pharmaceuticals steps into mRNA technology and actively integrates macromolecular pharmaceutical technology

Multinational biotech company Polaris signed an industry sponsored research agreement with UC Irvine’s (UCI) Vaccine Research and Development Center to fund “Fluvid,” a universal messenger RNA (mRNA) influenza and …

Read More
Scroll to Top
This site is registered on wpml.org as a development site.